Tailored Drug Titration Using Artificial Intelligence
| 适应症 | Hypertension |
|---|---|
| 分期 | 不适用 |
| 申办方 | Optima Integrated Health |
| 状态 | 已完成 |
| 受试者人数 | 165 人 |
| 干预（药物） | optima4BP |
| 开始日期 | 2020年2月18日 |
| 完成日期 | 2022年12月30日 |
| 结果公布日 | 2026年7月20日 |
摘要
The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.
Systolic Blood Pressure [SBP] (mmHg) Measured Remotely [Time Frame: 0 - 6 Months]
| optima4BP | 17.5 ± 5 mmHg |
|---|---|
| Standard of Care (SOC) | 15.1 ± 3.5 mmHg |
| optima4BP | 7.8 ± 0.7 mmHg |
| Standard of Care (SOC) | 5.8 ± 1.1 mmHg |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
- Improving Hypertension Medication Adherence for Older Adults — University of Arizona
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
- SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca